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Attention deficit hyperactivity disorder (ADHD) is a highly heritable neuropsychiatric condi-
tion, but it has been difficult to identify genes underlying this disorder. This study aimed to
explore genetics of ADHD in an ethnically homogeneous Norwegian population by means
of a genome-wide association (GWA) analysis followed by examination of candidate loci.
Materials and Methods
Participants were recruited through Norwegian medical and birth registries as well as the
general population. Presence of ADHD was defined according to DSM-IV criteria. Genotyp-
ing was performed using Illumina Human OmniExpress-12v1 microarrays. Statistical analy-
ses were divided into several steps: (1) genome-wide association in the form of logistic
regression in PLINK and follow-up pathway analyses performed in DAPPLE and INRICH
softwares, (2) SNP-heritability calculated using genome-wide complex trait analysis
(GCTA) tool, (3) gene-based association tests carried out in JAG software, and (4) evalua-
tion of previously reported genome-wide signals and candidate genes of ADHD.
Results
In total, 1.358 individuals (478 cases and 880 controls) and 598.384 autosomal SNPs were
subjected to GWA analysis. No single polymorphism reached genome-wide significance.
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The strongest signal was observed at rs9949006 in the ENSG00000263745 gene
(OR=1.51, 95% CI 1.28–1.79, p=1.38E-06). Pathway analyses of the top SNPs implicated
genes involved in the regulation of gene expression, cell adhesion and inflammation.
Among previously identified ADHD candidate genes, prominent association signals were
observed for SLC9A9 (rs1393072, OR=1.46, 95% CI = 1.21–1.77, p=9.95E-05) and TPH2
(rs17110690, OR = 1.38, 95% CI = 1.14–1.66, p=8.31E-04).
Conclusion
This study confirms the complexity and heterogeneity of ADHD etiology. Taken together
with previous findings, our results point to a spectrum of biological mechanisms underlying
the symptoms of ADHD, providing targets for further genetic exploration of this complex
disorder.
Introduction
Attention deficit hyperactivity disorder (ADHD) is one of the most common and most herita-
ble childhood onset psychiatric conditions [1, 2]. Children with ADHD are at high risk of de-
veloping antisocial behavior, substance abuse and other psychiatric disorders, consequently
presenting difficulties in their education and social integration [3]. Traditionally, ADHD was
considered to be a childhood disorder that usually diminishes in adolescents. However, follow-
up studies in the last few decades have clearly shown that many children continue to exhibit
signs of ADHD in their adulthood as well [4, 5]. Persistence of ADHD poses a significant issue
for society, with serious health-related, economic and personal consequences [6–9].
Despite the high heritability of 70–80% [1, 10, 11], the genetic architecture of ADHD is still
largely unknown. So far, association studies of ADHD have implicated risk variants that (1)
generally tend to have small effect sizes or be rare, (2) often refer to co-occurring conditions
and (3) lack consistent replication [12, 13].
Neurotransmitters have been the major target for candidate gene association studies in
ADHD. Nominal significance was reported for the dopamine-related genes SLC6A3 and
DRD5; serotonin-related genes SLC6A4 and HTR1B; as well as a synaptic vesicle membrane
docking SNAP-25 gene [14, 15]. However, effects of these genes are likely to be rather small
and they have not been decisively supported by previous studies [16–19].
Genome-wide association (GWA) study is a useful tool for discovering novel risk variants
as it allows a hypothesis-free interrogation of the entire genome. Several GWA analyses have
been performed in order to identify ADHD risk loci using either case-control or family-based
designs [13, 20], but to date there is no single nucleotide polymorphism (SNP) reaching the
stringent genome-wide significance threshold (p<5.00E-08). Nonetheless, the top SNPs from
previous GWA analyses include candidate genes that encode the cell adhesion protein CDH13
[16, 17, 21], the glutamate receptor GRM5 [22], the solute carrier protein SLC9A9 [23], the
cholinergic receptor CHRNA7 [24] as well as the potassium-channel regulators KCNIP1,
KCNIP4 and KCNC1 [16, 17].
The lack of robust genetic association findings in ADHDmay be explained by its polygenic,
multifactorial nature, with both common and rare variants likely contributing small effects to
its etiology [24–26]. An additional potentially important factor may be the genetic heterogene-
ity of ADHD age-related subtypes (childhood versus adult ADHD) which may have different
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underlying genetic mechanisms. It is well established, for example, that age influences ADHD-
relevant cognitive performance [27, 28]. In addition, it has been suggested that age can modu-
late the association of the SLC6A3 gene with ADHD [29–31]. Nonetheless, persistent ADHD
also has its onset in childhood and an overlap in genetics of childhood and adult ADHDmay
be observed from previous GWA studies. For example, CDH13 encoding the cell adhesion pro-
tein T-cadherin is among the strongest associated candidate genes in both childhood and adult
ADHD [16, 17]. Thus, performing GWA analysis on childhood and adult ADHD samples
combined, as well as utilizing GWAS results in the examination of possibly involved biological
processes, may help our understanding of genetic mechanisms underlying both childhood and
adult ADHD.
This study aimed to identify genetic susceptibility loci of ADHD utilizing GWAS in a Nor-
wegian sample of both childhood and adult ADHD, and investigate potential underlying mech-
anisms by pathway analyses.
Materials and Methods
Subjects
Recruitment was conducted at two sites in Norway: University of Bergen (UiB, Bergen, Nor-
way) and the Norwegian Institute of Public Health (NIPH) in collaboration with the University
of Oslo (UiO, Oslo, Norway). All participants provided signed informed consent form. The
study was approved by the Norwegian regional medical research ethics committee West (IRB
#3 FWA00009490, IRB00001872) as well as South East Norway, part C.
Recruitment of participants at UiB is described in details elsewhere [9]. In short, ADHD pa-
tients were recruited through a Norwegian national medical registry as well as by psychologists
and psychiatrists working at out-patient clinics. ADHD diagnosis was defined according to
DSM-IV criteria. Controls were randomly recruited through the Norwegian Medical Birth reg-
istry. All participants provided either blood or saliva samples for DNA extraction.
Participants at NIPH/UiO were selected through a screening procedure based on question-
naires from the Mother and Child Cohort Study (MoBa), resulting in 1195 children being clini-
cally assessed [32]. The Norwegian Mother and Child Cohort Study (MoBa) is a prospective
population-based pregnancy cohort study conducted by the Norwegian Institute of Public
Health. Participants were recruited from all over Norway from 1999–2008 [33]. The Preschool
Age Psychiatric Assessment [34] was used to determine symptoms of ADHD in accordance
with DSM-IV criteria. Presence of significant symptoms of ADHD was defined as either 1)
meeting all the symptom criteria for a DSM-IV-TR diagnosis, 2) meeting all the DSM-IV-TR
symptom criteria for a diagnosis, but without report of impairment or 3) meeting at least three
symptom criteria for a diagnosis in addition to report of impairment. DNA was available for
701 of the 1195 participants.
Additional control samples were recruited at UiO as parts of the following studies: Themati-
cally Organized Psychosis Research (TOP) [35], LifeSpan Cognition and Plasticity through the
Lifespan [36] and Neurocognitive Development [37], and Akershus University Hospital
(AHUS) based memory study [38]. Healthy subjects in the TOP study were randomly selected
using national records and the Primary Care Evaluation of Mental Disorders (PRIME-MD).
None of the control subjects had a history of moderate/severe head injury, neurological disor-
der, mental retardation or an age outside the age range of 18–65 years. Subjects were excluded
if they or any of their close relatives had a lifetime history of a severe psychiatric disorder
(schizophrenia, bipolar disorder and major depression), a history of medical problems thought
to interfere with brain function (hypothyroidism, uncontrolled hypertension and diabetes), or
significant illicit drug use.
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Participants from the Cognition and Plasticity through the Lifespan and Neurocognitive
Development studies were recruited through newspaper advertisements, at local schools and
among students and employees of the University of Oslo. The controls were screened for psy-
chiatric disorders as well as neurological illnesses.
The AHUS sample consists of controls from longitudinal studies of age-related cognitive
impairment. Any cognitive symptoms and somatic or psychiatric disease history with possible
cognitive impact were among the exclusion criteria [38].
All individuals (cases and controls) recruited at UiB and within MoBa were screened for
ADHD, while all other participants were screened for major neuropsychiatric disorders only
(schizophrenia, bipolar disorder, major depression and mental retardation).
Genotyping and quality control
Participants were genotyped on either Human OmniExpress-12v1-1_B (Illumina, San Diego,
CA, USA) or Human OmniExpress-12v1_H (Illumina, San Diego, CA, USA) platforms. Geno-
typing was performed according to the standard Illumina protocol at Decode facility (Reykja-
vik, Iceland). Genotypes were assigned according to the standard Illumina protocol in
GenomeStudio software, version V2011.1.
Individuals exhibiting high rates of genotype missingness (above 98%) or genome-wide het-
erozygosity (outside mean±3SD of the sample); cryptic relatedness (PI_HAT above 15%) or
non-European ancestry were excluded from the analyses. Sex check was performed based on
the homozygocity estimate of X chromosome markers implemented in PLINK. Given high
concordance between the reported and estimated sex (>98% in our dataset), this method was
also used to impute the missing sex information.
SNPs exhibiting high rates of missingness (above 95%), minor allele frequency (MAF)
below 1% or failing Hardy-Weinberg equilibrium test (p<1.00E-05) were excluded from
the analyses.
Genome-wide association
Each SNP was tested for association with ADHD in the form of logistic regression assuming an
underlying additive model and adjusted for gender as implemented in PLINK [39]. Because
participants were genotyped on different arrays, SNPs showing high discrepancy in their fre-
quencies between the two arrays (p<1.00E-05) were excluded from GWA analysis. A covariate
corresponding to each genotyping array was included in the regression model when testing for
association. Genomic control [40] was applied to check for possible population stratification.
QQ plot was constructed to study the distribution of test statistics. A significance threshold of
5.00E-08 was adopted to correct for multiple testing.
Expression Quantitative Trait Locus (eQTL) analysis
The top SNPs (p<1.00E-04) identified in genome-wide association tests were subjected to
eQTL identification in Genevar software, using cis-eQTL SNP mode [41]. Expression-genotype
pairs were extracted from HapMap3 data [42]. The reference source was set to Ensembl. The
analyses were performed under default settings (Spearman’s correlation coefficient = 1, win-
dow around the SNPs of interest = 1 million basepairs, p-value threshold 1.00E-03).
Estimation of SNP-heritability
SNP-heritability was estimated using the GCTA software [43]. Genetic similarity threshold
was set to 0.05. The analysis model included sex and genotyping array as covariates.
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Enrichment analysis
To evaluate if any known biological pathways were implicated by our GWAS results, intervals
around top SNPs (p<1.00E-04) were tested for enrichment in Gene Ontology (GO) nodes
using the INRICH software [44]. Enrichment analysis performed in INRICH was based on the
number of unique genes within an association interval that are over-represented in at least one
defined gene-set. Association intervals were determined as the linkage-disequilibrium (LD) in-
dependent regions around the top associated SNPs. These regions were constructed by tagging
the top SNPs in PLINK (tagging r2 threshold was set to 0.2, and each tags were constrained to
be within a megabase). Defined gene-sets were determined as GO nodes. The minimum num-
ber of genes in a set was set to 5, while the maximum to 200 genes. Interval overlap was limited
to 20 kbp up- or down-stream of a gene. Random interval sets, each approximately matching
the associated intervals in terms of the number of SNPs and overlapping genes, were generated
ten thousand times. To correct the empirical gene-set, p-value bootstrapping-based re-sam-
pling (5,000 times) was applied.
Protein-protein link evaluation
Using the same association intervals as determined in INRICH enrichment analysis, we as-
sessed possible physical interactions between proteins encoded in those intervals. The analysis
was performed using DAPPLE software [45]. DAPPLE identifies direct and indirect networks
from proteins encoded in associated intervals by utilizing experimentally validated, protein-
protein interaction databases. As a result, DAPPLE assesses if the connectivity between associ-
ated proteins would be greater than expected by chance.
Gene-based association tests
Gene-based association tests were performed using JAG software [46, 47]. For each gene, the
test statistic was defined as the sum of the—log10 association p-values of individual SNPs anno-
tated to each of the genes. Gene annotation of the variants included a 2000 basepair region
around each gene. Only genes with at least two annotated SNPs were considered for the
analysis.
To ensure an unbiased interpretation of the results, 10.000 permutations were carried out.
The statistics of each gene were computed for each permutation and the final gene-based p-
value was calculated as the proportion of test statistics in the permuted data that was higher
than the original test statistic. Genes reaching p-value below 1.00E-03 with the initial 10.000
permutations were further permuted 10 million times.
For permutations and to account for LD effects between examined SNPs, we utilized the ge-
notype data of the European ancestry samples from the 1000 Genomes project [48].
Analyses of previous ADHD GWA and candidate gene studies
After performing our analyses, we looked up previously published ADHD GWAS hits and
SNPs in ADHD candidate genes in our results. Utilizing the catalogue of published GWAS
(http://www.genome.gov/gwastudies/, December 2014), we curated a list of SNPs reaching p-
value 1.00E-05 in previous genome-wide studies of ADHD. For ADHD candidate genes, we
adopted the gene list constructed by Brookes et al [49]. These genes were annotated in our data
with a 2.000 basepair window on each end of a gene.
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Meta-analysis of our main findings and PGC ADHD GWAS results
We have meta-analyzed our top hits (p-value< 1.00E-04) with the results of a large-scale
ADHDmeta-analysis completed by psychiatric genetics consortium (PGC) [50]. Meta-analysis
were performed in the form of random effects regression implemented in PLINK.
Results
Genome-wide association
After quality control, there were 1.358 individuals (478 cases and 880 controls) and 598.467
SNPs available for the analysis. Details of the final sample are summarized in Table 1. Overall,
the age distribution was comparable among the cases and controls (37.24% of the cases and
29.38% of the controls were children).
No variant reached genome-wide significance (p<5.00E-08). Table 2 details the top SNPs
with association p-value being less than 1.00E-05 and S1A Table those reaching p-value below
1.00E-04. None of the main hits (p<1.00E-05) showed significant frequency difference be-
tween the two genotyping arrays utilized in this study (S3 Table). There was no inflation of cal-
culated p-values observed (λ = 1.01). Figs 1 and 2 depict the QQ- and Manhattan-plots
reflecting the results of the performed GWAS.
Expression Quantitative Trait Locus (eQTL) analysis
We subjected our top seven SNPs detailed in Table 2 to eQTL evaluation in Genevar software.
Matching transcripts were identified for two SNPs in an intergenic region on chromosome 3
(rs12497166 and rs1019897), rs17137481 in the TRIM36 gene, rs9949006 in
ENSG00000263745 gene and rs2856244 in the vicinity of our top hit within ZBTB16 gene.
None of the probes revealed significant (p<1.00E-03) effects on any gene expression. S1 Fig
summarizes the results of these analyses.
Estimation of SNP-heritability
After removal of individuals showing genetic similarity over 0.05, 448 cases and 817 controls
were analyzed. Overall, the SNP-heritability of ADHD was estimated to be 28% (standard
error = 26%, p = 0.140).
Table 1. Properties of the individuals subjected to GWAS in this study.












UiB 300 205 505 29.88 (9.14) 55.84 B
MoBa/Preschool ADHD
(NIPH)
104 243 347 3.46 (0.12) 46.40 H
MoBa/Preschool ADHD
(NIPH)
74 156 230 3.48 (0.11) 49.57 B
UiO controls none 191 191 31.65 (18.09) 52.08 H
none 85 85 65.22 (9.21) 54.02 B
Total 478 880 1358
Genotyping array B refers to Human OmniExpress-12v1-1_B (Illumina, San Diego, CA, USA) and genotyping array H refers to Human OmniExpress-
12v1_H (Illumina, San Diego, CA, USA). SD refers to standard deviation, UiB refers to University of Bergen and UiO refers to University of Oslo.
doi:10.1371/journal.pone.0122501.t001
GWAS of ADHD in Norway
PLOS ONE | DOI:10.1371/journal.pone.0122501 April 13, 2015 6 / 17
Enrichment analysis
There were 64 SNPs showing association of p<1.00E-04 and 45 LD-independent intervals
were constructed (S1 Table). Out of these 45 intervals, 24 were intergenic and, thus, excluded
from the analyses.
Overall, the associated intervals revealed enrichment in three GO pathways: rRNA process-
ing (GO:0006364, p = 2.00E-03), skeletal system development (GO:0001501, p = 0.025) and
central nervous system development (GO:0007417, p = 0.047). In particular, the enrichment
was due to association endowment in the following genes: UTP23, EXOSC8, ZBTB16, POSTN
and ADAM23 (Table 3). Although none of these pathways reached significance after correcting
for multiple testing, many implicate biological functions that are potentially relevant to
ADHD.
Protein-protein link evaluation
The LD-independent associated intervals contained 28 genes (S2 Table) that were tested for
protein-protein interaction in DAPPLE software. DAPPLE could not identify 3 genes: OR3A2,





OR 95% CI p-value
3 147951120 rs12497166 intergenic T 0.68 0.58–0.80 4.95E-
06
3 147967689 rs9836412 intergenic A 0.68 0.57–0.80 4.18E-
06
3 147978393 rs1019897 intergenic C 0.67 0.57–0.79 2.55E-
06
3 147986944 rs9834616 intergenic A 0.68 0.58–0.81 6.25E-
06
5 114497623 rs17137481 missense variant (N456S) in TRIM36 C 2.22 1.56–3.16 9.08E-
06
11 113620851 rs2856244 Intronic variant in ZBTB16 A 1.47 1.24–1.75 8.69E-
06
18 1906608 rs9949006 Long non-protein coding gene
(ENSG00000263745)
T 1.51 1.28–1.79 1.38E-
06
Chromosomal position is specified in Build 36 (hg18). OR refers to odds ratio and 95%CI refers to 95% confidence interval. TRIM36 refers to tripartite
motif containing 36 gene. ZBTB16 refers to zinc finger and BTB domain containing 16 gene.
doi:10.1371/journal.pone.0122501.t002
Fig 1. QQ plot. This figure represents the distribution of p-values observed in the presented genome-wide
association study of ADHD. The shaded area represents the 95% confidence interval.
doi:10.1371/journal.pone.0122501.g001
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DYTN and LOC200726. Analysis of the remaining genes revealed no direct connections
among proteins in our associated intervals. Nonetheless, several significant non-direct interac-
tors were identified. This may suggest that although proteins encoded by genes in our associat-
ed intervals do not interact directly with each other, they may represent converging hubs of
ADHD-relevant protein networks. Table 4 and Fig 3 present the details of DAPPLE results.
Gene-based association tests
In total, our dataset contained 16.546 genes with at least two annotated variants that were test-
ed for gene-based association. Seventeen genes revealed p-values below 1.00E-03, with the
most prominent signal observed for CCRN4L (p = 2.00E-07). We observed three SNPs annotat-
ed to CCRN4L that contributed to the detected gene-wide signal: rs10212985 (p = 1.48E-03),
rs13108158 (p = 1.53E-03) and rs1112828 (p = 3.11E-04). S4 Table reports the details of the
top hits in the gene-based analysis.
Analyses of previous ADHD GWA and candidate gene studies
Based on the information of the catalogue of published GWAS studies (http://www.genome.
gov/gwastudies/), we curated a list of 159 SNPs with reported p-value 1.00E-05 in previous
GWA analyses of ADHD. Out of these 159 SNPs, only two revealed significant result with p-
value below 0.05 in our analysis: rs2241685 and rs7463256 (p-value in our study is 4.76E-03
and 0.01 respectively). The first SNP is an intronic variant in theMYT1L gene found to be
Fig 2. Manhattan plot. Red line represents genome-wide significance threshold of 5.00E-08, while the blue
line corresponds to the suggestive threshold of p = 1.00E-05.
doi:10.1371/journal.pone.0122501.g002
Table 3. Results of enrichment analysis.




Associated Intervals Gene list














This table details the GO pathways that revealed significant enrichment prior to correction for multiple testing.
doi:10.1371/journal.pone.0122501.t003
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associated with adult ADHD (reported p = 8.00E-06), while the second SNP is an intronic
one in the CHMP7 gene and was noted in a meta-analysis of ADHD in children (reported
p = 3.00E-06) [16, 21]. Since no odds ratio and standard error was reported, we were unable to
meta-analyze our data with these previously published results. S5 Table contains details of all
top hits (p-value 1.00E-06) from previous GWA analyses pursued in our study.
To analyze SNPs within previously reported ADHD candidate genes, we utilized the list of
51 such genes curated by Brookes et al [49]. Overall, our data contained 826 SNPs in these can-
didate genes and 16 of them revealed p-values below 0.01 in the following genes: ADRA1A,
DDC, PER2, SLC9A9, STX1A and TPH2 (S6 Table). SLC9A9 revealed 7 significant SNPs with
the strongest signal being rs1393072 (OR = 1.46, 95% CI = 1.21–1.77, p = 9.95E-05). TPH2 was
noted as the second most prominent gene with 5 significant SNPs and its strongest signal being
rs17110690 (OR = 1.38, 95% CI = 1.14–1.66, p = 8.31E-04). Gene-based association tests
Table 4. Results of protein-protein link evaluation in DAPPLE. List of indirect interactors.
Protein number of binding
proteins





CDH1 2 CTNND2, BOC 0.001 0.008 Calcium-dependent cell-adhesion protein
CDH2 2 CTNND2, BOC 0.001 0.008 Calcium-dependent cell-adhesion protein
IL6 2 PRLR, ZBTB16 0.001 0.008 Cytokine functioning in inflammation and the
maturation of B cell
EIF2S2 2 EIF3H, ZBTB16 0.005 0.039 Eukaryotic translation initiation factor 2
CTNNB1 3 CTNND2, BOC,
CSNK1A1L
0.005 0.039 Adherens junction protein, adhesion between cells
Presented p-values reflect the probability that by chance individual interactors would be as connected to seed proteins (S2 Table) as was observed in the
constructed network.
doi:10.1371/journal.pone.0122501.t004
Fig 3. Protein-protein interaction network build from proteins encoded in associated intervals. The
colored, full circles represent proteins encoded in associated intervals (S2 Table). The smaller, grey circles
represent interactors of indirect connections. Functionally, the DAPPLE-constructed diagram can be divided
into two main groups: group “A”mostly involved in the regulation of gene expression and inflammation; and
group “B”mostly involved in cell adhesion.
doi:10.1371/journal.pone.0122501.g003
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affirmed these observations as only SLC9A9 and TPH2 genes reached overall p-values below
0.05 (p = 0.047 for SLC9A9 based on 209 SNPs and p = 0.015 for TPH2 based on 32 SNPs).
S2 Fig depicts regional plots representing observed association signals annotated to SLC9A9
and TPH2 in this study.
Meta-analysis of our main findings and PGC ADHD GWAS results
Apart from examining previously reported ADHD candidate genes and GWAS hits, we also
performed a meta-analysis of our top SNPs (p<1.00E-04) with the data from a large-scale
ADHD GWASmeta-analysis conducted by PGC. Out of the 64 most significant SNPs observed
in our study (S1A Table), 47 were available in the PGC data. The strongest signal was observed
for rs11121424 (p = 4.32E-05) in the LOC100506022 gene (S7 Table).
Discussion
This is the first ADHD GWA analysis performed in the Norwegian population. Similarly to
previous ADHD studies, we found no genome-wide significant SNPs at the standard genome-
wide significance threshold (p<5.00E-08). However, several nominally significant (p<1.00E-
05) variants were identified (Table 2). In addition, pathways analyses of associated intervals re-
vealed a number of biological processes as well as protein interactions that are potentially rele-
vant in the pathogenesis of ADHD (Tables 3 and 4).
The strongest signal in this GWAS was observed for rs9949006 on chromosome 18
(OR = 1.51, 95% CI 1.28–1.79, p = 1.64E-06). This SNP is a transcript variant of the non-cod-
ing RNA ENSG00000263745 gene. We have evaluated a possible function of rs9949006 using
SNPinfo webserver (http://snpinfo.niehs.nih.gov), where no obvious gene-expression regulat-
ing activity was observed for this SNP. Nonetheless, non-protein coding RNAs play a critical
role in regulation of gene expression and have been associated with a spectrum of human disor-
ders, including neurodegeneration [51] and schizophrenia [52]. Non-coding RNA genes have
also been observed among top hits in previous ADHD GWAS (S5 Table). In addition, it has
been recently observed that SNPs previously associated with neurological and psychiatric con-
ditions may be highly concentrated in the regions of long non-protein coding RNA genes [53].
Among our most significant SNPs, we have also noted a region on chromosome 3 as well as
the TRIM36 and ZBTB16 genes (Table 2). The region on chromosome 3 can be identified as
the regulatory ENSR00001484632 transcription factor binding feature, while both TRIM36
and ZBTB16 encode proteins that are expressed in the brain and are involved in the cell cycle
regulation [54]. Functional evaluation of these SNPs in SNPinfo server (http://snpinfo.niehs.
nih.gov) revealed possible gene-expression altering activity for rs17137481 only. This missense
variant in the TRIM36 gene is predicted to be benign by both PolyPhen and SIFT. However,
this SNP (rs17137481) is in strong LD (r2 = 0.826 in CEU population) with rs4146835, pre-
dicted to be a transcription-binding site (SNPinfo server). In addition, rs17137481 is also in
strong LD with rs3805596 and rs2974527 (r2 = 0.885 and 0.826 respectively in CEU popula-
tion), which are located in 3’-UTR region of the TRIM36 gene and are anticipated to be micro-
RNA binding sites (SNPinfo server).
The TRIM36 protein is a multidomain E3 ubiquitin ligase that interacts with centromere
protein-H and may be involved in differentiation and development during embryogenesis [54,
55]. This protein may be involved in protein–protein interactions [56], with a function in cell
adhesion [57], the process implicated in the pathogenesis of ADHD by several previous studies
[16, 17, 21, 58].
The variant in ZBTB16 is an intronic SNP involved in nonsense mediated RNA decay. Simi-
larly to TRIM26, ZBTB16 is involved in cell cycle regulation by encoding a transcriptional
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repressor that was identified in patients with acute promyelocytic leukemia [59], while muta-
tions in mice have revealed that ZBTB16 also plays an important role in skeletal development
and spermatogonial stem-cell maintenance [60, 61]. Deletions of the chromosomal region con-
taining ZBTB16 are known to associate with mental retardation, skeletal defects and genital hy-
poplasia (OMIM # 612447) [62]. Interestingly, ZBTB16 is associated with ethanol preference
in mice [63]. It is well established that human ADHD patients have an increased risk of alcohol
dependence and substance abuse [9, 64].
Apart from being involved in cell cycle regulation, both TRIM36 and ZBTB16 are also
among genes in the reactome pathways of Class I MHC mediated antigen processing & presen-
tation and Immune System (REACT_75842.1 and REACT_75820.1). Class I MHC pathways
may be involved in brain development [65]. In addition, several neuro-immunological hypoth-
eses have been offered as a possible explanation for the development of neuro-psychiatric dis-
orders [66–68], including ADHD [69]. It is also known that some immune conditions (e.g.
asthma) often co-occur with ADHD [70].
Examining enrichment of associated intervals among GO nodes revealed possible engage-
ment of mechanisms involved in rRNA processing as well as skeletal and central nervous sys-
tem development in the pathogenesis of ADHD (Table 3). The strongest enrichment was
observed for rRNA processing (p = 2.00E-03) due to association signals in the regions contain-
ing UTP23 and EXOSC8 genes. Both UTP23 (encoding a small subunit processome compo-
nent) and EXOSC8 (encoding exosome component) are involved in multiple cellular RNA
processing and degradation events. Enrichment for these genes may suggest that, similarly to
other neuro-developmental condition, gene expression regulating components could be in-
volved in the etiology of ADHD [52, 71]. This observation is also in line with our main finding
being located within a long non-protein coding RNA gene.
Interestingly, the ZBTB16 gene, where we noted some of our most prominent single point
associations, was contained by the region contributing to the enrichment observed for the de-
velopment of both skeletal and central nervous systems. In addition, signals in two other re-
gions, encompassing POSTN and ADAM23 genes, also conferred enrichment for these two
nodes. POSTN encodes the extracellular matrix glycoprotein periostin that is found in blood
and peripheral tissues, while ADAM23 encodes a membrane-anchored protein (metallopro-
tease). Protein products of both of these genes are involved in cell adhesion, cell-cell and cell-
matrix interactions, playing an important role in a variety of biological processes, including
ADHD-relevant neurogenesis.
Since GO nodes are based on gene annotations only, we also conducted a protein-protein
link exploration in DAPPLE software that utilizes experimental data. The results of this analy-
sis did not show any direct interaction between proteins encoded by our nominally ADHD-as-
sociated loci. However, a number of significant intermediate interactors was recognized, with
five of them surviving correction for multiple testing: CDH1 and CDH2, IL6, EIF2S2 and
CTNNB1 (Table 4). Thus, it could be hypothesized that these genes highlight a protein network
that may be impaired in ADHD. These protein-protein interactions may implicate two major
networks (Fig 3): (1) cell adhesion (CDH1, CDH2, CTNNB1, CTNND2, BOC and CSNK1A1L
genes); and (2) gene expression regulation and inflammation (ADAM23, YWHAZ, EIF2S2,
IL6, EIF3H, ZBTB16, RPS27A, TRPC4, CCDC85B and PRLR genes). The above pathways are
in line with previous findings showing that dysregulation during brain development (e.g. neur-
ite outgrowth) may be important in the pathology of ADHD [13, 16, 25, 72].
Association with ADHD in this study was also examined in the form of gene-based tests.
The most significant signal was noted for CCRN4L (p = 2.00E-07) that encodes a component
of the circadian clock or downstream effector of clock function. In mammals, the circadian
timing system controls many aspects of behavior and physiology, with its disruptions being
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implicated in major neuro-psychiatric disorders (including ADHD) at behavioral, endocrine
and molecular levels [73–75].
To investigate the contribution of common SNPs to ADHD liability, we have estimated
SNP-heritability using GCTA software. Similarly to previous observation in the large sample of
European ancestry [76], our evaluation revealed the heritability of 28%. However, it is impor-
tant to note that the large standard error in our estimations mirror the limited power to reliably
determine the SNP-heritability.
The results of this study have been evaluated in the light of previously identified ADHD
candidate genes and genome-wide association scans. While none of the previous GWAS hits
replicated in our study (S5 Table), two candidate genes displayed several signals of association.
SLC9A9 showed the strongest evidence of association with an intronic rs1393072, p-value of
9.95E-05 (S6 Table and S2 Fig). SLC9A9 encodes a sodium/hydrogen exchanger and may be of
particular relevance to ADHD. This gene was found to be associated with a combined type of
ADHD and it was noted among main signals in previous genome-wide linkage and association
studies of ADHD [13, 49, 77]. Another candidate gene with a number of association signals ob-
served in this study was TPH2 gene (S6 Table and S2 Fig). It encodes the enzyme tryptophan
hydroxylase 2 that initiates serotonin synthesis in the nervous system [78]. Similarly to
SLC9A9, the association between ADHD and TPH2 has previously been reported in numerous
studies [19, 49, 79–81], although some negative results have also been reported [82].
This study should be viewed in the light of its limitations. There was no genome-wide signif-
icant observation for any SNP. One explanation for this could be that our study is of modest
size (478 cases and 880 controls) and has examined common (MAF>1%) variants only. Thus,
it has low power to detect common variants of small effect sizes.
Although assuming that performing GWAS on joined childhood and adult ADHD samples
may improve our understanding of ADHD, it may also be a potential limitation. Thus, clinical
heterogeneity may weaken the association signals [83]. This may occur, for example, due to the
use of different assessment protocols; or due to the real genetic heterogeneity among different
subtypes of ADHD [84]. It is currently unknown to which degree genetic and phenotypic het-
erogeneity impacts gene discovery in ADHD, and, in particular, how the genetics of ADHD
change across the lifetime (from childhood to persistent ADHD).
In summary, we did not identify any gene loci reaching genome-wide significance, but
found several promising candidates. Although replication in independent samples is war-
ranted, these findings underline the genetic and phenotypic heterogeneity of ADHD. Taken to-
gether with previous findings, our results confirm the connection between biological processes
important for brain development and ADHD, providing targets for further genetic exploration
of this complex disorder.
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